Study identifier:1839IL/0712
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Randomised Placebo-controlled Phase II Trial of preoperative Therapy with gefitinib (Iressa®/ZD1839) and Epirubicin-Cyclophosphamide in Patients with primary operable (T2-T3) Oestrogen Receptor negative Breast Cancer
Breast Cancer
Phase 2
No
gefitinib
Female
160
Interventional
18 Years +
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The aim of the study is to estimate the effect of preoperative gefitinib on the complete pathological response rate in primary estrogen receptor negative breast cancer at the time of surgery.
Location
Location
Århus C, Denmark
Location
Herlev, Denmark
Location
København N, Denmark
Location
København Ø, Denmark
Location
Vejle, Denmark
Location
Oslo, Norway
Location
Trondheim, Norway
Location
Lund, Sweden
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.